



Resource impact template

Resource impact

Published: 10 July 2024

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for treating moderate to severe atopic dermatitis:

- [Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over](#) (2024) NICE technology appraisal guidance 986
- [Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis](#) (2022) NICE technology appraisal guidance 814
- [Baricitinib for treating moderate to severe atopic dermatitis](#) (2021) NICE technology appraisal guidance 681
- [Dupilumab for treating moderate to severe atopic dermatitis](#) (2018) NICE technology appraisal guidance 534